Modulation of Neurological Deficits and Expression of Glutamate Receptors during Experimental Autoimmune Encephalomyelitis after Treatment with Selected Antagonists of Glutamate Receptors
Figure 2
Scores of the neurological symptoms during the acute phase of EAE and after treatment with antagonists of glutamate receptors. Antagonist doses were as follows: amantadine 100 mg/kg b.w./day, memantine 60 mg/kg b.w./day, LY 367385 10 mg/kg b.w./day, and MPEP 10 mg/kg b.w./day. These doses were administered separately (a) or in combination (b) from 5 to 11 d.p.i. Neurological signs were recorded until recovery of the control EAE group at 25 d.p.i. The values indicate neurological score ± SD. Results are combined data from four to eight animals in each group. ; compared with untreated EAE rats.
